Efgartigimod Is an Effective Treatment for Triple‐Seronegative Generalized Myasthenia Gravis: A Report of Three Patients

Documenti analoghi

• Sustained Minimal Manifestations With Extended Interval Dosing of Efgartigimod in Seronegative Myasthenia Gravis: Case Report
  di: Teppei Komatsu, et al.
  Pubblicazione: (2025)
• Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study
  di: Jing Lin, et al.
  Pubblicazione: (2026)
• Safety and Effectiveness of Eculizumab in Patients With Refractory Ocular or Ocular‐Predominant Myasthenia Gravis: A Case Series
  di: Shiyu Shi, et al.
  Pubblicazione: (2026)
• Comparison of the Quantitative Myasthenia Gravis and Myasthenia Gravis Activity of Daily Living Scores From a Clinical Practice Perspective
  di: Wanqing Wu, et al.
  Pubblicazione: (2025)
• Non‐Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia Gravis
  di: Marc Abi Aoun, et al.
  Pubblicazione: (2026)